BFFTF Projected Dividend Yield

Biofrontera AG ( OTCBB : BFFTF )

Biofrontera is a holding company. Through its subsidiaries, Co. is an international biopharmaceutical company. Co.'s primary product is Ameluz®, which is a prescription drug for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. Ameluz® is also for the photodynamic therapy treatment of field cancerization, as well as superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome and for treatment of actinic keratosis with Ameluz® in combination with daylight photodynamic therapy (i.e., using natural daylight to activate the drug).

20 YEAR PERFORMANCE RESULTS